Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.

However, patients who achieved disease control after taxane treatment had a tendency to present better efficacy of subsequent NAB‐paclitaxel treatment than patients in whom taxane treatment had failed, although the results did not reach statistical significance (DCR 72.4% vs. 47.6%, P = 0.075) (Table 3 ).

also in 111,027 other papers